ANNUAL GENERAL MEETING
Investors back Mediclinic resolutions
Just more than 87% of shareholders approve the amended directors’ remuneration policy
The shareholders of Mediclinic voted in favour of all 22 resolutions and also approved a 4.70p final dividend, at the company’s annual general meeting held in London on Tuesday.
Mediclinic has a primary listing on the main market of the London Stock Exchange, with secondary listings on the JSE and the NSX in Namibia.
The company’s total ordinary shares in issue on July 25 was 737,243,810 at 10p each.
Just more than 87% of shareholders voted to approve the amended directors’ remuneration policy, with 4.05% of the investors voting against.
Nitrogen Fund Managers MD Rowan Williams said the voting in of the updated remuneration policy showed that shareholders had confidence in the management of the company, even though Mediclinic’s performance had been disappointing in the past cycle.
CEO Danie Meintjes announced his resignation at the meeting, while former executive director and group chief financial officer of Mediclinic International Jurgens Myburgh was elected as a director.
All re-elected directors got the thumbs-up from a majority of investors. Despite a request from a shareholder to consider potentially employing another auditing company, PwC was re-elected as auditors of the firm.
About 11% of voters were against authorisation for the directors to make political donations. Nonexecutive chairman Edwin Hertzog told investors on Tuesday that political donations would only happen in Switzerland, where it was not out of the ordinary and in small amounts.
Mediclinic’s share price has been on the rise this week and on Thursday, it gained 2.2% to close at R129.35.